Bioventus (NASDAQ:BVS) Hits New 1-Year High – What’s Next?

Bioventus Inc. (NASDAQ:BVS)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $9.69 and last traded at $9.6480, with a volume of 20136 shares traded. The stock had previously closed at $9.42.

Analysts Set New Price Targets

A number of equities analysts recently commented on BVS shares. Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reissued a “hold (c-)” rating on shares of Bioventus in a research note on Monday, December 29th. Barrington Research increased their target price on Bioventus from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Friday, March 6th. Craig Hallum raised their target price on Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Finally, CJS Securities began coverage on Bioventus in a report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Bioventus has an average rating of “Buy” and a consensus price target of $14.00.

Bioventus Trading Up 3.1%

The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.19 and a current ratio of 1.70. The stock has a market cap of $807.39 million, a price-to-earnings ratio of 29.39 and a beta of 0.70. The company’s 50 day simple moving average is $8.74 and its two-hundred day simple moving average is $7.83.

Bioventus (NASDAQ:BVS) last issued its earnings results on Thursday, March 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.02. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. The company had revenue of $157.90 million during the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Insider Buying and Selling

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total value of $105,480.00. Following the transaction, the director owned 44,997 shares in the company, valued at $395,523.63. The trade was a 21.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 33.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bioventus

Several large investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after purchasing an additional 1,538 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Bioventus by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock worth $1,486,000 after purchasing an additional 26,103 shares in the last quarter. Legal & General Group Plc increased its position in Bioventus by 100.9% during the second quarter. Legal & General Group Plc now owns 71,409 shares of the company’s stock worth $473,000 after buying an additional 35,873 shares during the last quarter. Rhumbline Advisers increased its position in Bioventus by 20.6% during the second quarter. Rhumbline Advisers now owns 65,093 shares of the company’s stock worth $431,000 after buying an additional 11,133 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in Bioventus by 32.5% during the second quarter. Marshall Wace LLP now owns 211,695 shares of the company’s stock valued at $1,401,000 after buying an additional 51,951 shares in the last quarter. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.